+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Nuclear Medicine Diagnostics Market by Radiopharmaceutical (11C Choline, 18F DcfpyL, 18F Fluciclovine), Modality (Pet, Spect), End User, Indication - Global Forecast 2025-2030- Product Image
Prostate Cancer Nuclear Medicine Diagnostics Market by Radiopharmaceutical (11C Choline, 18F DcfpyL, 18F Fluciclovine), Modality (Pet, Spect), End User, Indication - Global Forecast 2025-2030- Product Image
Sale

Prostate Cancer Nuclear Medicine Diagnostics Market by Radiopharmaceutical (11C Choline, 18F DcfpyL, 18F Fluciclovine), Modality (Pet, Spect), End User, Indication - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5639599
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The prostate cancer nuclear medicine diagnostics market is evolving, driven by breakthroughs in radiopharmaceutical innovation, advanced imaging technologies, and changing healthcare demands. Senior decision-makers must understand how these changes reshape diagnostic precision, strategic investment, and supply chain resilience.

Market Snapshot: Growth Trajectory and Competitive Dynamics

The Prostate Cancer Nuclear Medicine Diagnostics Market grew from USD 1.15 billion in 2024 to USD 1.31 billion in 2025. It is expected to continue growing at a CAGR of 12.86%, reaching USD 2.39 billion by 2030. Growth is underpinned by rising prevalence, rapid clinical adoption of novel radiotracers, and technological transition to digital and hybrid imaging platforms. Industry leaders are implementing robust strategies to address clinical demands and evolving reimbursement frameworks, positioning themselves to capture value as advanced diagnostics become standard practice.

Scope & Segmentation of the Prostate Cancer Nuclear Medicine Diagnostics Market

This report offers comprehensive segmentation, presenting strategic analysis across radiopharmaceuticals, imaging modalities, end-user categories, clinical applications, and geographic distribution. Insights enable decision-makers to identify opportunities for asset allocation, partnership, and product differentiation.

  • Radiopharmaceuticals: 11C choline, 18F DcfpyL, 18F fluciclovine, 68Ga PSMA, emerging agents including 18F PSMA-1007 and 64Cu PSMA
  • Modalities: PET (digital PET and time-of-flight PET), SPECT (conventional SPECT, SPECT CT)
  • End Users: Academic research institutes, diagnostic centers, hospitals
  • Clinical Indications: Biochemical recurrence detection, initial staging, treatment monitoring
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (notable countries include UK, Germany, UAE, Saudi Arabia, South Africa), Asia-Pacific (China, India, Japan, Australia, South Korea, and several Southeast Asian nations)
  • Leading Companies: GE HealthCare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Cardinal Health, Inc., Bayer AG, Lantheus Holdings, Inc., Bracco Imaging S.p.A., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Isotope Technologies Munich SE

Key Takeaways for Strategic Decision-Making

  • Advanced radiotracers, such as high-affinity PSMA compounds, are shifting diagnostic standards, delivering improved lesion detection and localization in clinical workflows.
  • The adoption of digital PET detectors and time-of-flight technology supports higher-resolution imaging, boosting clinical confidence and operational throughput.
  • Strategic partnerships between radiopharmaceutical developers and imaging equipment manufacturers accelerate the validation and adoption of next-generation agents.
  • Hybrid imaging modalities, combining functional and anatomical data, enable more nuanced patient assessments from initial diagnosis through therapy monitoring.
  • Market participants are investing in localized manufacturing and distribution strategies to address both logistic challenges and regional variations in regulatory and reimbursement environments.
  • Geographic differences are significant; North America and Asia-Pacific lead in uptake, while resource constraints present opportunities for cost-optimized implementation elsewhere.

Assessing Tariff Impact on Supply Chains

The implementation of 2025 United States tariff measures has increased costs for key inputs, including radiopharmaceuticals and nuclear imaging equipment. Domestic providers respond by diversifying sourcing, renegotiating supply contracts, and considering regional manufacturing hubs. This environment has prompted innovation in production methods and stimulated collaborations that improve supply chain resilience. Organizations able to adapt their procurement and operational structures are positioned to maintain consistent access despite evolving regulatory and trade conditions.

Methodology & Data Sources

This research was built from primary interviews with clinicians, radiopharmacists, procurement leaders, and imaging specialists, complemented by detailed secondary review of scientific literature, technical white papers, regulatory records, and tariff data. Analytical validation included triangulation of utilization patterns, scenario simulations, and expert panel reviews, providing a robust evidence base for findings and recommendations.

Why This Report Matters

Decision-makers gain:

  • Actionable intelligence on trends and technology adoption critical for competitive positioning in prostate cancer nuclear medicine diagnostics
  • Detailed segmentation supporting focused product, partnership, and investment strategies tailored to region and clinical application
  • Clarity on threats and opportunities related to tariffs and supply chain adjustments, supporting proactive risk management and operational planning

Conclusion

The prostate cancer nuclear medicine diagnostics market is in a dynamic phase, shaped by innovation, policy shifts, and regional healthcare priorities. Strategic alignment across technologies and partnerships will be essential for sustained growth and improved diagnostic care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of PSMA-targeted PET imaging in early detection and staging of recurrent prostate cancer
5.2. Advances in radiolabeled small molecule therapeutics improving targeted radionuclide therapy outcomes in mCRPC
5.3. Deployment of next generation digital PET/CT scanners enhancing image resolution and quantitative accuracy in prostate cancer diagnostics
5.4. Regulatory approval and commercialization of novel radionuclide conjugates targeting PSMA for theranostic applications in prostate cancer patients
5.5. Growth of hybrid PET/MRI systems to reduce radiation exposure while improving soft tissue characterization in prostate imaging
5.6. Emergence of artificial intelligence algorithms for automated interpretation and prognostic risk stratification in prostate cancer nuclear scans
5.7. Increasing adoption of personalized dosimetry software for optimizing safety and efficacy of lutetium-177 radioligand therapy in clinical practice
5.8. Collaborations between academic institutions and pharma companies accelerating clinical trials of novel alpha-emitting PSMA therapies in prostate cancer management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Prostate Cancer Nuclear Medicine Diagnostics Market, by Radiopharmaceutical
8.1. Introduction
8.2. 11C Choline
8.3. 18F DcfpyL
8.4. 18F Fluciclovine
8.5. 68Ga Psma
8.6. Emerging Agents
8.6.1. 18F Psma 1007
8.6.2. 64Cu Psma
9. Prostate Cancer Nuclear Medicine Diagnostics Market, by Modality
9.1. Introduction
9.2. Pet
9.2.1. Digital Pet
9.2.2. Time Of Flight Pet
9.3. Spect
9.3.1. Conventional Spect
9.3.2. Spect Ct
10. Prostate Cancer Nuclear Medicine Diagnostics Market, by End User
10.1. Introduction
10.2. Academic Research Institute
10.3. Diagnostic Center
10.4. Hospital
11. Prostate Cancer Nuclear Medicine Diagnostics Market, by Indication
11.1. Introduction
11.2. Biochemical Recurrence Detection
11.3. Initial Staging
11.4. Treatment Monitoring
12. Americas Prostate Cancer Nuclear Medicine Diagnostics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. GE HealthCare Technologies Inc.
15.3.2. Siemens Healthineers AG
15.3.3. Koninklijke Philips N.V.
15.3.4. Cardinal Health, Inc.
15.3.5. Bayer AG
15.3.6. Lantheus Holdings, Inc.
15.3.7. Bracco Imaging S.p.A.
15.3.8. Telix Pharmaceuticals Limited
15.3.9. Eckert & Ziegler Strahlen- und Medizintechnik AG
15.3.10. Isotope Technologies Munich SE
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET: RESEARCHAI
FIGURE 24. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET: RESEARCHSTATISTICS
FIGURE 25. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET: RESEARCHCONTACTS
FIGURE 26. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 93. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 94. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 95. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 96. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 97. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 98. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 99. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 100. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 101. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 102. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 103. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 108. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 109. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 110. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 111. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 112. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 113. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 114. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 115. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 116. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 117. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 180. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 181. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 182. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 183. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 184. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 185. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 186. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 187. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 188. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 189. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. GERMANY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 194. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 195. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 196. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 197. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 198. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 199. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 200. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 201. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 202. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 203. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. FRANCE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 222. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 223. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 224. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 225. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 226. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 227. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 228. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 229. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 230. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 231. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. ITALY PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 236. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 237. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 238. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 239. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 240. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 241. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 242. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 243. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 244. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 245. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. SPAIN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024

Samples

Loading
LOADING...

Companies Mentioned

  • GE HealthCare Technologies Inc.
  • Siemens Healthineers AG
  • Koninklijke Philips N.V.
  • Cardinal Health, Inc.
  • Bayer AG
  • Lantheus Holdings, Inc.
  • Bracco Imaging S.p.A.
  • Telix Pharmaceuticals Limited
  • Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Isotope Technologies Munich SE

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.31 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.39 Billion
Compound Annual Growth Rate12.8%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2025 - Product Image

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Radiopharmaceuticals Market Growth Analysis Report - Market Size, Share, Forecast Trends and Outlook (2025-2034) - Product Image

Radiopharmaceuticals Market Growth Analysis Report - Market Size, Share, Forecast Trends and Outlook (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Nuclear Medicine Market Report and Forecast 2025-2034 - Product Image

Nuclear Medicine Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Radiopharmaceuticals Market - Products and Applications - Product Image

Radiopharmaceuticals Market - Products and Applications

  • Report
  • 307 Pages
  • Global
From
Nuclear Medicine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Nuclear Medicine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From

About the Prostate Cancer Nuclear Medicine Diagnostics Market

Prostate cancer nuclear medicine diagnostics is a segment within the broader field of medical diagnostics focused on using nuclear medicine techniques to detect and evaluate prostate cancer. Nuclear medicine is a medical specialty that employs small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and sometimes treat diseases. In prostate cancer diagnosis, these radiopharmaceuticals are designed to target specific molecules associated with the presence of cancer cells, such as the prostate-specific membrane antigen (PSMA). Imaging technologies like Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are utilized in conjunction with these radiotracers to visualize the distribution of the radioactive material within the prostate gland and surrounding tissues. This enables physicians to detect the presence and extent of prostate cancer, thereby guiding treatment decisions and prognostication. Key players in the prostate cancer nuclear medicine diagnostics market include companies that specialize in the production of radiopharmaceuticals, as well as those that manufacture the imaging equipment used in the diagnostic process. Some prominent companies in this market are Advanced Accelerator Applications (a subsidiary of Novartis), Blue Earth Diagnostics (a Bracco company), Progenics Pharmaceuticals (part of Lantheus Medical Imaging), IsoRay Medical, and Bayer AG. These companies engage in research and development to improve the specificity and sensitivity of nuclear diagnostic agents for prostate cancer and strive to create advanced imaging systems for more precise disease characterization. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.